BioXcel Therapeutics, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$9.7M
Doctors Paid
2,768
Transactions
5,408
2024 Total
$5.2M
Payment Breakdown by Category
Research$8.5M (88.2%)
Consulting$420,398 (4.3%)
Food & Beverage$159,119 (1.6%)
Travel$91,244 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8.5M | 161 | 88.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $455,983 | 184 | 4.7% |
| Consulting Fee | $420,398 | 52 | 4.3% |
| Food and Beverage | $159,119 | 4,205 | 1.6% |
| Travel and Lodging | $91,244 | 794 | 0.9% |
| Honoraria | $12,690 | 12 | 0.1% |
Payments by Type
Research
$8.5M
161 transactions
General
$1.1M
5,247 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK PERIOD IN SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA | $2.3M | 0 | 18 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY ANDSAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK TREATMENT PERIOD INSUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA WHO REQUIRE AT LEASTMODERATE TO FULL ASSISTANCE WITH ACTIVITIES OF DAILY LIVING | $2.0M | 0 | 16 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK TREATMENT PERIOD IN SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA WHO REQUIRE AT LEAST MODERATE TO FULL ASSISTANCE WITH ACTIVITIES OF DAILY LIVING | $1.5M | 0 | 10 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE EFFICACY AND SAFETY OF BXCL501 OF AGITATION ASSOCIATED WITH PEDIATRIC SCHIZOPHRENIA AND BIPOLAR DISORDER | $1.2M | 0 | 11 |
| A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype | $457,648 | 0 | 41 |
| A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. | $456,719 | 0 | 44 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE EFFICACY AND SAFETY OF BXCL501 IN AGITATION ASSOCIATED WITH PEDIATRIC SCHIZOPHRENIA AND BIPOLAR DISORDER | $448,946 | 0 | 4 |
| EVALUATION OF BXCL501 PLACEBO INSTRUCTIONS FOR USE AND COMPREHENSION OF TRAINING FOR CAREGIVERS AND PARTICIPANTS WITH AGITATION ASSOCIATED WITH ALZHEIMERS DEMENTIA PARTICIPATING IN STUDIES INVESTIGATING AT-HOME ADMINISTRATION | $91,092 | 0 | 3 |
| BXCL501401 | $81,795 | 0 | 14 |
Payments by Medical Specialty
Top Paid Doctors — Page 5
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Unknown Provider | — | — | $190.14 | $0 |
| Dr. Franklin Bordenave, M.d, M.D | Psychiatry | New Orleans, LA | $187.71 | $0 |
| Dr. Sidney Smith, M.d, M.D | Psychiatry | Metairie, LA | $179.08 | $0 |
| Lynn Reyman, Md, MD | Emergency Medicine | Morristown, NJ | $178.87 | $0 |
| Dr. Danielle Amona, Md, MD | Pediatrics | Long Branch, NJ | $178.87 | $0 |
| Dr. Nicole Maguire, D.o, D.O | Emergency Medicine | Newark, NJ | $178.87 | $0 |
| Toni Costanzo, Pa-C, PA-C | Medical | Newark, NJ | $178.87 | $0 |
| Dr. Navin Ariyaprakai, M.d, M.D | Emergency Medicine | Newark, NJ | $178.87 | $0 |
| William Dalsey, Md, MD | Emergency Medicine | Lakewood, NJ | $178.87 | $0 |
| Dr. Christopher Freer, Do, DO | Internal Medicine | Berkeley Heights, NJ | $178.87 | $0 |
| Dr. Cynthia Ko, M.d, M.D | Student in an Organized Health Care Education/Training Program | New York, NY | $177.80 | $0 |
| Vijay Singh, Do, DO | Student in an Organized Health Care Education/Training Program | Las Vegas, NV | $176.17 | $0 |
| Colleen Barry, Fnp-C, FNP-C | Family | Bowling Green, OH | $173.97 | $0 |
| Dr. Irfan Ahmed, Md, MD | Psychiatry | Toledo, OH | $173.97 | $0 |
| Dr. Herman Soong, Md, MD | Psychiatry | New Orleans, LA | $173.95 | $0 |
| Kirsten Sizemore, Np, NP | Nurse Practitioner | Leitchfield, KY | $169.50 | $0 |
| Dr. Leszek Michalewicz, M.d, M.D | Psychiatry | New Orleans, LA | $168.55 | $0 |
| Dr. Miguel Sanchez, Md, MD | Dermatology | New York, NY | $167.04 | $0 |
| Mrs. Kristin Lee, Aprn, APRN | Registered Nurse | Bowling Green, KY | $166.22 | $0 |
| Dr. Bens Sandaire, D.o, D.O | Psychiatry | Warren, MI | $165.10 | $0 |
| Mrs. Anna Tran, Pmhnp-Bc, PMHNP-BC | Psychiatric/Mental Health | Chesterfield, MO | $161.11 | $0 |
| Karen Lyda, Np, NP | Adult Health | Aurora, CO | $160.84 | $0 |
| Dr. Christopher Bondick, Do, DO | Emergency Medicine | Garden City, MI | $154.81 | $0 |
| Dr. Mohsen Akhlaghi, M.d, M.D | Emergency Medicine | Houston, TX | $154.78 | $0 |
| Afrina Zaman | Student in an Organized Health Care Education/Training Program | Brooklyn, NY | $154.12 | $0 |
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. has made $9.7M in payments to 2,768 healthcare providers, recorded across 5,408 transactions in the CMS Open Payments database. In 2024, the company paid $5.2M. The top product by payment volume is IGALMI ($8.7M).
Payments were distributed across 98 medical specialties. The top specialty by payment amount is Psychiatry ($395,547 to 540 doctors).
Payment categories include: Food & Beverage ($159,119), Consulting ($420,398), Research ($8.5M), Travel & Lodging ($91,244).
BioXcel Therapeutics, Inc. is associated with 2 products in the CMS Open Payments database.